Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 3 study of VX-659 triple combination drug in people with CF 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation , protocol number VX17-659-102

  This randomized, placebo-controlled study will be taking place at multiple care centers across the U.S. It will evaluate the effectiveness, safety, and effect on the body of the drug VX-659 in combination with tezacaftor and ivacaftor. It is for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.

  • Age:

    12 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    32 weeks

• Mucociliary ClearanceEnrolling

  Cohorts 1 and 2 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis CQBW276X2201

  This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety and tolerability of the inhaled drug QBW276 as well as how the body processes the drug.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    6

  • Length of Participation:

    14 days

• Anti-InflammatoryEnrolling

  Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    189 days

• Anti-InfectiveEnrolling

  STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-IP-15

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of different lengths of IV treatment for pulmonary exacerbations in people with CF.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    35 days

• ObservationalEnrolling

  Rare mutation cell collection (RARE) , protocol number RARE-OB-16

  This study is taking place at multiple care centers across the U.S. Researchers will collect and make available for study cells from people with rare CFTR mutations.

  • Age:

    2 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    1 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.